Company profile: Delenex Therapeutics
1.1 - Company Overview
Company description
- Provider of therapeutic antibody fragments targeting serious medical diseases with high unmet need, designed for local/topical application to deliver the benefits of antibody therapy with limited systemic exposure, built on clinically validated technology.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Delenex Therapeutics
Numab Therapeutics
HQ: Switzerland
Website
- Description: Provider of antibody-based therapeutics for severe diseases, including chronic inflammation and cancer, leveraging a plug-and-play platform to predictably yield ready-to-develop multispecific biotherapeutics. Offerings include NM26 for atopic dermatitis, NM49 for cancer, and λ-Cap (stable human antibody fragments) and MATCH (modular scaffolding for multispecific formats) technologies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Numab Therapeutics company profile →
Kedrion Biopharma
HQ: United States
Website
- Description: Provider of plasma-derived medicinal products—clotting factors, albumin, and immunoglobulins—for treating hemophilia and immune deficiencies. Offers contract fractionation/manufacturing, technology transfer to build local plasma collection and fractionation, BioSC virus/prion safety studies (PCR, contaminants in cell cultures, in vitro, protein characterization), and pharmacovigilance.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kedrion Biopharma company profile →
Diamyd Medical
HQ: Sweden
Website
- Description: Provider of antigen-specific immunotherapies and regenerative therapies for Type 1 Diabetes based on the GAD molecule and GABA technology. Products include Diamyd to preserve insulin production and Remygen for regeneration/immunomodulation. Offers GMP-manufactured GAD65 protein for preclinical research and conducts DIAGNODE-3 (Phase III intralymphatic Diamyd) and DiaPrecise (Phase II prevention) trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diamyd Medical company profile →
Achilles Therapeutics
HQ: United Kingdom
Website
- Description: Provider of patient-specific cancer immunotherapies that harness the immune system to target truncal tumor neoantigens. Offers PELEUS, an AI-powered bioinformatics platform to identify clonal neoantigens; VELOS, a manufacturing process to create clonal neoantigen-reactive T cell (cNeT) products; and cNeT cell therapies targeting multiple clonal neoantigens to treat cancer while sparing healthy tissue.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Achilles Therapeutics company profile →
MolMed
HQ: Italy
Website
- Description: Provider of medical biotechnology research, development and clinical validation of novel anticancer therapies. The pipeline includes antitumour therapeutics in clinical and preclinical development, including Zalmoxis (TK), a cell-based therapy enabling bone marrow transplants from partially compatible donors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MolMed company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Delenex Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Delenex Therapeutics
2.2 - Growth funds investing in similar companies to Delenex Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Delenex Therapeutics
4.2 - Public trading comparable groups for Delenex Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →